Cellectar Biosciences, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Cellectar Biosciences, Inc. (CLRB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $76.20 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-03-04
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $20.17K, a 16.64% increase year-over-year.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $19.41K, a 16.56% increase year-over-year.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $18.67K, a 16.45% increase year-over-year.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $17.96K, a 16.34% increase year-over-year.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $76.20K, a 16.50% increase from fiscal 2024.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $65.41K, a 12.68% increase from fiscal 2023.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $58.05K, a 35.81% decline from fiscal 2022.
- Cellectar Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $90.43K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $20.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $39.58K derived: sum of 2 quarters · filed 2026-03-04 | $58.24K derived: sum of 3 quarters · filed 2026-03-04 | $76.20K 10-K · filed 2026-03-04 |
| 2025-09-30 | $19.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $38.08K derived: sum of 2 quarters · filed 2025-11-13 | $56.03K 10-Q · filed 2025-11-13 | $73.33K derived: sum of 4 quarters · filed 2026-03-04 |
| 2025-06-30 | $18.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $36.63K 10-Q · filed 2025-08-14 | $53.92K derived: sum of 3 quarters · filed 2026-03-04 | $70.57K derived: sum of 4 quarters · filed 2026-03-04 |
| 2025-03-31 | $17.96K 10-Q · filed 2025-05-13 | $35.25K derived: sum of 2 quarters · filed 2026-03-04 | $51.90K derived: sum of 3 quarters · filed 2026-03-04 | $67.93K derived: sum of 4 quarters · filed 2026-03-04 |
| 2024-12-31 | $17.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $33.94K derived: sum of 2 quarters · filed 2026-03-04 | $49.97K derived: sum of 3 quarters · filed 2026-03-04 | $65.41K 10-K · filed 2026-03-04 |
| 2024-09-30 | $16.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $32.68K derived: sum of 2 quarters · filed 2025-11-13 | $48.12K 10-Q · filed 2025-11-13 | $63.40K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $16.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $31.47K 10-Q · filed 2025-08-14 | $46.75K derived: sum of 3 quarters · filed 2025-08-14 | $61.48K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $15.44K 10-Q · filed 2025-05-13 | $30.72K derived: sum of 2 quarters · filed 2025-05-13 | $45.45K derived: sum of 3 quarters · filed 2025-05-13 | $59.66K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $15.28K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $30.02K derived: sum of 2 quarters · filed 2025-03-13 | $44.22K derived: sum of 3 quarters · filed 2025-03-13 | $58.05K 10-K · filed 2025-03-13 |
| 2023-09-30 | $14.73K derived: 10-Q 9 month − 10-K/A 6 month · filed 2024-11-18 | $28.94K derived: sum of 2 quarters · filed 2024-11-18 | $42.77K 10-Q · filed 2024-11-18 | $66.65K derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | $14.21K derived: 10-K/A 6 month − 10-K/A 3 month · filed 2024-10-29 | $28.03K 10-K/A · filed 2024-10-29 | $51.92K derived: sum of 3 quarters · filed 2024-10-29 | $74.93K derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-03-31 | $13.83K 10-K/A · filed 2024-10-29 | $37.71K derived: sum of 2 quarters · filed 2024-10-29 | $60.73K derived: sum of 3 quarters · filed 2024-10-29 | $82.90K derived: sum of 4 quarters · filed 2024-10-29 |
| 2022-12-31 | $23.89K derived: 10-K/A 12 month − 10-K/A 9 month · filed 2024-10-29 | $46.90K derived: sum of 2 quarters · filed 2024-10-29 | $69.07K derived: sum of 3 quarters · filed 2024-10-29 | $90.43K 10-K/A · filed 2024-10-29 |
| 2022-09-30 | $23.01K derived: 10-K/A 9 month − 10-K/A 6 month · filed 2024-10-29 | $45.19K derived: sum of 2 quarters · filed 2024-10-29 | $66.55K 10-K/A · filed 2024-10-29 | |
| 2022-06-30 | $22.18K derived: 10-K/A 6 month − 10-K/A 3 month · filed 2024-10-29 | $43.53K 10-K/A · filed 2024-10-29 | ||
| 2022-03-31 | $21.36K 10-K/A · filed 2024-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |